May 10, 2024
eMedClub News
May 9,The official website of the Center for Drug Evaluation (CDE) shows that BW-20507 Injection from Hangzhou Bolin Pharmaceutical Technology Co., Ltd. has received clinical tacit approval for the proposed treatment of chronic hepatitis B virus infection. It is reported that,Hangzhou Bolin Pharmaceutical Technology Co., Ltd.ArgoArgo's subsidiary,BW-20507 is a small interfering RNA (siRNA) drug independently developed by the company.▲ Image Source:CDE Official Website
September 13, 2023BW-20507A Phase 1/2 Clinical Trial Has Been Initiated in Australia to Evaluate in Healthy Subjects and Chronic Hepatitis B Virus（HBV）Safety, Tolerability, Pharmacokinetics, and Dosing in Infected IndividualsIncrementResearch.
Hepatitis B virus generally infects normal liver cells by binding to cell receptors on the liver cell membrane. After the viral DNA enters the host cell nucleus, it forms cccDNA under the action of DNA polymerase. Then, using the infected liver cells as a "production base," it continuously produces new hepatitis B viruses and cccDNA, infecting more normal liver cells.Throughout the replication process, the infected liver cells continuously express a series of specific proteins that are recognized as antigens by the human immune system, including Hepatitis B e antigen (HBeAg) and Hepatitis B surface antigen (HBsAg). HBsAg itself is not infectious but plays a crucial role in the process of Hepatitis B virus infecting liver cells.Trends in mRNA Drug Development
Progress in the Development of Self-Replicating mRNA Vaccines for Herpes Zoster
Development and Application of Personalized Tumor mRNA Vaccines
Progress in the Development of RSV mRNA Vaccines
Strategies for Developing mRNA Therapeutic Vaccines for HPV-Related Tumors
Development of Liver-Targeted Small Interfering RNA (siRNA) Drugs for Dyslipidemia
Development of siRNA Drugs for Chronic Hepatitis B Virus Infection
Research Progress on Liver-Targeted PCSK9 Dual-Strand Small Interfering RNA
Development Progress of Self-Assembled Exosome Delivery of siRNA for the Treatment of Huntington's Disease
Technical Advantages and Application Prospects of Engineered tRNA
Research on Nucleolin Aptamer-Drug Conjugates Based on Clinical Combination Therapy
The Technical Development and Application Prospects of Circular RNA
lncRNA-Based Extrahepatic Targeted Delivery Technology
Roundtable: Exploring the Future Applications of mRNA Drugs
Roundtable: Trends in Next-Generation RNA Drug Technology Innovation
Limited Time Offer
Free Tickets
18701871600 (Manager Wang)
15572286596 (Manager Yuan)
15221150919 (Manager He)
siRNA drugs are an emerging new technology drug in recent years, with the advantages of multiple druggable targets, strong efficacy, good safety, low dosing frequency, and a wide range of indications, covering cardiovascular diseases, rare diseases, neurological disorders, and viral hepatitis., ophthalmic diseases, tumors, etc., have become one of the frontier pharmaceutical fields with extremely high development potential worldwide.Argo Biopharma, established in 2021, is a clinical-stage biotechnology company dedicated to developing a new generation of siRNA drugs to provide better treatment options for patients worldwide. In November 2023, Argo Biopharma announced the completion of its RMB 300 million Series A+ financing round.This round of financing was led by SDIC Capital, with participation from Huagai Capital, Yuanxi Haihe Fund, and existing shareholder Sanyi Innovation Investment.Over the past nearly three years, Argo has built a product pipeline including multiple siRNA candidate drugs, covering a wide range of indications.Currently, Argo has 5 siRNA drugs in clinical trial stages.。Notably, in January 2024, Argo announced that it had reached licensing and strategic collaboration agreements with Novartis for multiple RNAi projects.According to the agreement, Argo will receive an upfront payment of $185 million from Novartis, as well as milestone payments with a total potential transaction value of nearly $4.2 billion and tiered royalties on commercial sales.To seize the opportunities currently facing the industry and promote common development within the sector.MedCareer willJune 14-15, 2024Hosted in Nanjing2024 IBI EXPO Biopharmaceutical Innovation Industry Conference, and convene "The 3rd Nucleic Acid Drug Development Forum". This conference will invite pioneers and leaders in this field to focus on the latest research trends and advancements, deeply discuss and prospect the future development trends of nucleic acid drugs.2024 IBI EXPO Schedule Overview
Limited Time Offer
Free Tickets
Exciting Live Broadcast Preview
Press and hold to scan the QR code to participate immediately ↓
May 14th (Thursday) 18:30-19:50
Accelerated Release: Significant Speed-up in Quality Testing of Cellular Drugs
Statement and Copyright Notice
Statement:This article aims to convey industry development information and explore the forefront of biopharmaceutical advancements.The content of the article represents the author's views and does not represent the position of EMedClub, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.
Copyright Statement:This article is from the content team of Yima Guest. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form on other platforms is prohibited. For reprint authorization, please leave a message at the bottom of the article.
DianDian "Share”、“Like"and"In View", give me a little recharge~"
